NK Cell Licensing Diagnostic Kit for 6-Thiopurine Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammatory diseases like Crohn's disease are largely symptom-focused and lack personalized approaches due to unknown cellular mechanisms, leading to ineffective therapies and significant side effects.
Innovation Solution
The discovery of NK cell licensing by specific KIR and HLA gene combinations that reprogram NK cells to promote CD4+ T cell activation and TH17 differentiation, allowing for the development of kits and methods to identify patients likely to respond to 6-thiopurine therapy and tailor treatment regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If constant medication is administered to control chronic inflammation, then inflammation symptoms are reduced, but side effects increase and treatment effectiveness decreases
Solution Approach 1:
The patent applies preliminary action by performing genetic testing for KIR and HLA genes before initiating 6-thiopurine therapy. This allows identification of patients with specific genetic profiles (e.g., KIR2DL2/3 heterozygosity with HLA-C1) who are likely to respond to treatment, enabling physicians to prescribe the medication in advance with higher confidence of effectiveness and to avoid it in patients unlikely to benefit, thereby preventing unnecessary side effects.
Solution Approach 2:
The patent applies parameter changes by using genetic markers (KIR and HLA gene combinations) as selection criteria to stratify patients into different treatment groups. This changes the treatment parameter from a one-size-fits-approach to a personalized approach based on genetic parameters, allowing optimization of treatment effectiveness while minimizing side effects for each patient subgroup.
2Adaptability or versatility
If generic treatment regimens are used for chronic inflammatory diseases, then treatment coverage is broad, but personalization and efficacy are reduced
Solution Approach 1:
The patent performs preliminary genetic screening for KIR and HLA markers before treatment to identify patients with specific genetic profiles (e.g., KIR2DL2/3 heterozygosity combined with HLA-C1) who are likely to respond to 6-thiopurine therapy. This preliminary classification enables personalized treatment selection, improving both adaptability and reliability by matching the right treatment to the right genetic profile.
Solution Approach 2:
The patent applies local quality by creating distinct treatment subgroups based on specific genetic characteristics. Instead of a uniform treatment approach, the patent identifies local genetic subpopulations (e.g., patients with KIR2DL2/3 and HLA-C1) and tailors treatment recommendations to each subgroup, thereby achieving personalization without compromising overall treatment coverage.
3Loss of information
If the cellular mechanism of genetic contribution is unknown, then genetic studies can identify risk factors, but customized therapies cannot be developed
Solution Approach 1:
The patent uses genetic markers (KIR and HLA gene combinations) as intermediary indicators to bridge the gap between unknown cellular mechanisms and therapeutic application. By identifying specific genetic profiles (e.g., KIR2DL2/3 heterozygosity with HLA-C1) associated with treatment response, the patent creates a practical intermediary system that enables therapy customization without requiring complete understanding of the underlying cellular mechanisms.
Data Source
AI summary
NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein.